MAP Pharma files NDA for migraine drug
The 505(b)(2) filing of NDA was supported by the results from a Phase 3 FREEDOM-301 clinical trial which demonstrated that the patients who took Levadex, showed improvement at
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
The new company’s product portfolio comprises medicines targeting treatment of inflammatory diseases and conditions including atopic dermatitis, dry eye syndrome, interstitial cystitis, and lymphatic disorders, as well as